Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib

Blood (2025) 146 (Supplement 1): 1058.

https://doi.org/10.1182/blood-2025-1058

Published: 2025

Journal Articles

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

Blood (2025) 146 (Supplement 1): 170.

https://doi.org/10.1182/blood-2025-170

Published: 2025

Journal Articles

Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques

John Claiborne, Venkata Preetam Sandeep Kaduluri, Hua-Ling Tsai, Ivana Gojo, Amy DeZern, B. Douglas Smith, Tania Jain, Gabrielle Prince, Javier Bolanos-Meade, Ephraim Fuchs, Gabriel Ghiaur, Lukasz Gondek, William Dalton, Theodoros Karantanos, Ravi Varadhan, Mark Levis, Richard Jones, Jonathan Webster, Alex Ambinder

Blood (2025) 146 (Supplement 1): 44.

https://doi.org/10.1182/blood-2025-44

Published: 2025

Journal Articles

Outcomes of patients with relapsed/refractory FLT3mut+ Acute Myeloid Leukemia who resumed gilteritinib therapy after HSCT: Post hoc analysis from the ADMIRAL and COMMODORE trials

Mark Levis, Alexander Perl, Jianda Hu, Heeje Kim, Vladimir Ivanov, Hisayuki Yokoyama, Naoko Hosono, Er-Lie Jiang, Dong-Yeop Shin, Bartlomiej Getta, Ashish Bajel, Jamie Jung-Hee An, Dina Elsouda, Juan Ariza, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 42.

https://doi.org/10.1182/blood-2025-42

Published: 2025

Journal Articles

Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia

Justin Watts, Uma Borate, Mark Levis, Yasmin Abaza, Eunice Wang, Joshua Zeidner, Hongliang Cai, Bo Xu, Priya Robson, Akinobu Watanabe, Matthew Hitron, Jatin Shah, Hagop Kantarjian, Naval Daver

Blood (2025) 146 (Supplement 1): 765.

https://doi.org/10.1182/blood-2025-765

Published: 2025

Journal Articles

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Blood (2025) 146 (Supplement 1): 763.

https://doi.org/10.1182/blood-2025-763

Published: 2025

Journal Articles

DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors

Shirley Mo, Alex Ambinder, Amy DeZern, B. Douglas Smith, Ephraim Fuchs, Gabriel Ghiaur, Gabrielle Prince, Ivana Gojo, Javier Bolanos-Meade, Jonathan Webster, Lukasz Gondek, Richard Jones, Tania Jain, Theodoros Karantanos, William Dalton, Mark Levis

Blood (2025) 146 (Supplement 1): 1710.

https://doi.org/10.1182/blood-2025-1710

Published: 2025

Journal Articles

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

Blood (2025) 146 (Supplement 1): 654.

https://doi.org/10.1182/blood-2025-654

Published: 2025

Journal Articles

A plasma-based test for the measurable residual disease informs the response to treatment in AML patients

Blood (2025) 146 (Supplement 1): 1743.

https://doi.org/10.1182/blood-2025-1743

Published: 2025

Journal Articles

Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms

Laura Walsh, Venkata Preetam Sandeep Kaduluri, Amy DeZern, Gabrielle Prince, Jonathan Webster, Tania Jain, Theodoros Karantanos, William Dalton, Ivana Gojo, Alex Ambinder, B. Douglas Smith, Lukasz Gondek, Mark Levis, Gabriel Ghiaur

Blood (2025) 146 (Supplement 1): 5227.

https://doi.org/10.1182/blood-2025-5227

Published: 2025

Journal Articles

The Aza/Ven reshuffle

Mark Levis

Blood (2024) 144 (21): 2159–2160.

https://doi.org/10.1182/blood.2024026429

Published: 2024

Journal Articles

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Amy E. DeZern, Marianna Zahurak, Heather J. Symons, Kenneth R. Cooke, Carol Ann Huff, Tania Jain, Lode J. Swinnen, Philip H. Imus, Nina D. Wagner-Johnston, Richard F. Ambinder, Mark Levis, Leo Luznik, Javier Bolaños-Meade, Ephraim J. Fuchs, Richard J. Jones, Robert A. Brodsky

Blood (2023) 141 (25): 3031–3038.

https://doi.org/10.1182/blood.2023020435

Published: 2023

Includes: Supplemental data

Journal Articles

By any other name …

Mark Levis

Blood (2022) 140 (15): 1657–1658.

https://doi.org/10.1182/blood.2022018005

Published: 2022

Journal Articles

The Presence of SETBP1 , RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents

Theodoros Karantanos, Hua-Ling Tsai, Mark Levis, Ravi Varadhan, Richard J. Jones, Tania Jain

Blood (2021) 138 (Supplement 1): 1520.

https://doi.org/10.1182/blood-2021-151624

Published: 2021

Journal Articles

Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease

Sabine Kayser, Chiara Sartor, Marlise R. Luskin, Jonathan Webster, Fabio Giglio, Nydia Panitz, Andrew M. Brunner, Matthias Fante, Christoph Lutz, Daniel Wolff, Anthony D. Ho, Mark Levis, Richard F. Schlenk, Cristina Papayannidis

Blood (2021) 138 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2021-147446

Published: 2021

Journal Articles

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman

Blood (2021) 138 (Supplement 1): 691.

https://doi.org/10.1182/blood-2021-150743

Published: 2021

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Blood (2021) 138 (Supplement 1): 1303.

https://doi.org/10.1182/blood-2021-148129

Published: 2021

Journal Articles

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Vinod A. Pullarkat, Mark Levis, Gabriel N. Mannis, Stephen A Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald S. Cheung, Harry P. Erba

Blood (2021) 138 (Supplement 1): 1268.

https://doi.org/10.1182/blood-2021-148054

Published: 2021

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Blood (2021) 138 (Supplement 1): 1307.

https://doi.org/10.1182/blood-2021-150281

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Time from AML diagnosis to HCT and pre-HCT FLT3 inhibition impact pre-transplant MRD and benefit from post-HCT gilteritinib

Effect of FLT3 maintenance in older FLT3-ITD+ adults undergoing allogeneic HCT. a post hoc analysis of BMT CTN 1506

Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques

Outcomes of patients with relapsed/refractory FLT3mut+ Acute Myeloid Leukemia who resumed gilteritinib therapy after HSCT: Post hoc analysis from the ADMIRAL and COMMODORE trials

Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study

A plasma-based test for the measurable residual disease informs the response to treatment in AML patients

Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms

The Aza/Ven reshuffle

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

By any other name …

The Presence of SETBP1 , RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents

Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only